CME
Gain expert perspectives on the most clinically relevant data on breast gynecologic renal cell urothelial lung hepatobiliary and skin cancers presented at the 2022 ESMO Congress.
Physicians: Maximum of 1.25 AMA PRA Category 1 Credits™
Released: November 14, 2022
Expiration: November 13, 2023
Share
Nicoletta Colombo, MD, PhD
Associate Professor of Obsterics and Gynecology
European Institute of Oncology
University of Milan-Bicocca
Milan, Italy
Robert Motzer, MD
Attending Physician
Memorial Sloan-Kettering Cancer Center
New York, New York
Sapna P. Patel, MD
Dr. William Robinson Endowed Chair in Cancer Research
Director, Cutaneous Oncology and Cell Therapy for Solid Tumors
Professor of Medicine and Ophthalmology
University of Colorado
Aurora, Colorado
David Planchard, MD, PhD
Head of Thoracic Cancer Group
Department of Medical Oncology
Gustave Roussy
Villejuif, France
Elizabeth Plimack, MD, MS
Assistant Professor
Associate Member
Medical Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Rachna Shroff, MD, MS
Professor of Medicine
Chief, Section of GI Medical Oncology
Director, UACC Clinical Trials Office
The University of Arizona Cancer Center
Tucson, Arizona
Sara M. Tolaney, MD, MPH
Chief, Division of Breast Oncology
Associate Director, Susan F. Smith Center for Women’s Cancers
Senior Physician, Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts
Provided by Clinical Care Options, LLC
Supported by educational grants from
AstraZeneca
Bristol Myers Squibb
Exelixis, Inc.
Gilead Sciences, Inc.
Merck Sharp & Dohme Corp.
This program is intended for global physicians and other healthcare professionals who care for patients with cancer.
Upon completion of this activity, participants should be able to:
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Primary Author
Nicoletta Colombo, MD, PhD
Associate Professor of Obsterics and Gynecology
European Institute of Oncology
University of Milan-Bicocca
Milan, Italy
Nicoletta Colombo, MD:consultant/advisor/speaker: AstraZeneca, Clovis Oncology, Eisai, GlaxoSmithKline, Immunogen, Mersana, MSD/Merck, Novartis, Nuvation Bio, Onxerna, Pfizer, Pieris, Roche; researcher: AstraZeneca, Roche.
Robert Motzer, MD
Attending Physician
Memorial Sloan-Kettering Cancer Center
New York, New York
Robert Motzer, MD:consultant: Aveo, Eisai, Exelixis, Genentech, Merck, Roche.
Sapna P. Patel, MD
Dr. William Robinson Endowed Chair in Cancer Research
Director, Cutaneous Oncology and Cell Therapy for Solid Tumors
Professor of Medicine and Ophthalmology
University of Colorado
Aurora, Colorado
Sapna P. Patel, MD: consultant/advisor/speaker: Bristol-Myers Squibb, Castle Biosciences, Delcath, Immatics, Immunocore, Merck, Novartis, Reata, TriSalus Life Sciences; stock/stock options: Amgen, Pfizer; other financial or material support: Bristol-Myers Squibb, Cardinal Health, Foghorn Therapeutics, Ideaya, InxMed, Merck, Novartis, NCI, Provectus, Seagen, Syntrix Bio, TriSalus Life Sciences.
David Planchard, MD, PhD
Head of Thoracic Cancer Group
Department of Medical Oncology
Gustave Roussy
Villejuif, France
David Planchard, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Janssen, Novartis, Pfizer, Roche.
Elizabeth Plimack, MD, MS
Assistant Professor
Associate Member
Medical Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Elizabeth R. Plimack, MD, MS: consultant/advisor/speaker: Astellas, AstraZeneca, Aveo, Bristol-Myers Squibb, Calithera, EMD Serono, Exelixis, IMV Inc., Infinity Pharma, Janssen, MEI, Merck, Natera, Pfizer, Regeneron, Seagen; researcher: Astellas, Bristol-Myers Squibb, Genentech, Merck.
Rachna Shroff, MD, MS
Professor of Medicine
Chief, Section of GI Medical Oncology
Director, UACC Clinical Trials Office
The University of Arizona Cancer Center
Tucson, Arizona
Rachna Shroff, MD: consultant/advisor/speaker: AstraZeneca, Boehringer Ingelheim, CAMI, Clovis, Genentech, Incyte, QED; researcher: Bayer, Bristol-Myers Squibb, Exelixis, IMV Inc., Loxo, Merck, Novocure, Nucana, Pieris, QED, Rafael, Seagen, Taiho, Zymeworks.
Sara M. Tolaney, MD, MPH
Chief, Division of Breast Oncology
Associate Director, Susan F. Smith Center for Women’s Cancers
Senior Physician, Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts
Sara M. Tolaney, MD, MPH:consultant/advisor: 4D Pharma, ARC Therapeutics, AstraZeneca, Athenex, BeyondSpring, Blueprint Medicines, Bristol-Myers Squibb, Certara, Chugai, CytomX, Daiichi Sankyo, Eisai, Ellipses, Genentech/Roche, Gilead, Infinity, Lilly, Merck, Mersana, Myovant, Novartis, Odonate, OncoSec Medical, OncXerna, Pfizer, Reveal Genomics, Sanofi, Seagen, Umoja, Zentalis, Zetagen, Zymeworks; researcher: AstraZeneca, Bristol-Myers Squibb, Cyclacel, Eisai, Exelixis, Genentech/Roche, Gilead, Lilly, Merck, NanoString Technologies, Nektar, Novartis, Pfizer, Sanofi, Seagen.
The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 14, 2022, through November 13, 2023:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.
Program Medium
This program has been made available online.
The goal of this activity is to improve the understanding of healthcare professionals globally on recent practice-changing clinical data on the treatment of patients with cancer.